Oct 2, 2026 09:00AM
Oct 1, 2026 04:05PM
Oct 1, 2026 08:05AM
Oct 1, 2026 08:05AM
Sep 30, 2026 08:35AM
Sep 30, 2026 08:30AM
Sep 30, 2026 08:06AM Candel Therapeutics reports immune data for prostate cancer drug at ASTRO
Sep 30, 2026 08:05AM
Sep 10, 2026 08:05AM
Sep 10, 2026 08:05AM
Sep 1, 2026 04:05PM
Aug 26, 2026 08:05AM
Aug 13, 2026 08:05AM
Aug 3, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 3, 2026 08:05AM
Aug 3, 2026 08:05AM
Jul 29, 2026 08:05AM
Jul 8, 2026 04:05PM
Jul 1, 2026 04:05PM
Jun 30, 2026 08:05AM
Jun 30, 2026 08:05AM Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response
Jun 25, 2026 08:05AM
Jun 25, 2026 08:05AM
Jun 2, 2026 08:05AM
Jun 2, 2026 08:05AM
Jun 1, 2026 04:05PM
May 15, 2026 04:05PM
May 15, 2026 04:05PM Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge
May 14, 2026 08:05AM
May 13, 2026 08:05AM
May 4, 2026 08:05AM
May 4, 2026 08:05AM
May 1, 2026 04:05PM
Apr 29, 2026 08:05AM
Apr 29, 2026 08:05AM Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Apr 2, 2026 04:05PM
Mar 17, 2026 08:05AM
Mar 17, 2026 08:05AM
Mar 13, 2026 06:10AM
Mar 12, 2026 08:05AM
Mar 9, 2026 08:05AM
Mar 9, 2026 08:05AM Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annu
Mar 2, 2026 04:05PM
Feb 24, 2026 08:05AM
Feb 19, 2026 09:40PM
Feb 19, 2026 09:40PM
Feb 19, 2026 04:05PM
Feb 19, 2026 04:05PM
Feb 19, 2026 04:02PM Candel Therapeutics secures $100M royalty funding deal with RTW
Feb 19, 2026 04:01PM

334,274 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All